Literature DB >> 14736776

Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy.

F Gelisken1, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, K U Bartz-Schmidt.   

Abstract

AIMS: To report the clinicopathologic findings of surgically excised choroidal neovascularisation (CNV) three days after verteporfin photodynamic therapy (PDT).
METHODS: In three patients (three eyes) with age related macular degeneration, the CNV was surgically removed three days after PDT. The CNV specimens were examined by light microscopy.
RESULTS: The patients had subfoveal classic CNV. Fluorescein angiography revealed non-perfusion of the CNV after PDT and before surgery in all eyes. The light microscopy of the CNV membranes showed swollen and damaged endothelium. Thrombus formation or vascular occlusion in the CNV vessels was not detected.
CONCLUSION: PDT did not cause a thrombosis of the vessels within the CNV three days after PDT. Severe endothelial damage of the CNV was observed and is likely a primary effect of PDT. Non-perfusion of the CNV at this stage is possibly secondary to occlusion at a deeper level, namely the underlying feeding choroid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736776      PMCID: PMC1771999          DOI: 10.1136/bjo.2003.018754

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Histopathological changes following photodynamic therapy in human eyes.

Authors:  Ursula Schmidt-Erfurth; Horst Laqua; Ursula Schlötzer-Schrehard; Arne Viestenz; Gottfried O H Naumann
Journal:  Arch Ophthalmol       Date:  2002-06

2.  Retinal translocation and photodynamic therapy for age-related macular degeneration with classic choroidal neovascularization: a clinicopathologic case report.

Authors:  Hans E Grossniklaus; H Logan Brooks; Brian D Sippy; Pingbo Liu
Journal:  Retina       Date:  2002-12       Impact factor: 4.256

3.  Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy.

Authors:  N G Ghazi; N M Jabbour; Z C De La Cruz; W R Green
Journal:  Retina       Date:  2001       Impact factor: 4.256

4.  Theoretical investigation of the role of choriocapillaris blood flow in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.

Authors:  R W Flower; C von Kerczek; L Zhu; A Ernest; C Eggleton; L D Topoleski
Journal:  Am J Ophthalmol       Date:  2001-07       Impact factor: 5.258

5.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

6.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

Authors:  J W Miller; U Schmidt-Erfurth; M Sickenberg; C J Pournaras; H Laqua; I Barbazetto; L Zografos; B Piguet; G Donati; A M Lane; R Birngruber; H van den Berg; A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1999-09

7.  Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.

Authors:  U E Schnurrbusch; K Welt; L C Horn; P Wiedemann; S Wolf
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

8.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

9.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

10.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02
View more
  10 in total

1.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

2.  A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents.

Authors:  Mark C Butler; Patrick N Itotia; Jack M Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

3.  Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients.

Authors:  Ryuhei Hara; Takahiro Kawaji; Yasuya Inomata; Jin Tahara; Nina Sagara; Mikiko Fukushima; Hidenobu Tanihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-10       Impact factor: 3.117

4.  [Does acetylsalicylic acid have a negative influence on photodynamic therapy?].

Authors:  U Löw; J K Kohlhof; K W Ruprecht
Journal:  Ophthalmologe       Date:  2006-03       Impact factor: 1.059

5.  Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

Authors:  Rogério A Costa; Rodrigo Jorge; Daniela Calucci; Luiz A S Melo; José A Cardillo; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-28       Impact factor: 3.117

6.  Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes.

Authors:  K Petermeier; O Tatar; W Inhoffen; M Völker; B A Lafaut; S Henke-Fahle; F Gelisken; F Ziemssen; S Bopp; K U Bartz-Schmidt; S Grisanti
Journal:  Br J Ophthalmol       Date:  2006-04-13       Impact factor: 4.638

7.  Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Authors:  Eric Chen; David M Brown; Tien P Wong; Matthew S Benz; Eric Kegley; Joel Cox; Richard H Fish; Rosa Y Kim
Journal:  Clin Ophthalmol       Date:  2010-10-05

8.  Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases.

Authors:  S J Kang; I Schmack; H E Benson; H E Grossniklaus
Journal:  Br J Ophthalmol       Date:  2007-06-13       Impact factor: 4.638

9.  Severe decrease in visual acuity with choroidal hypoperfusion after photodynamic therapy.

Authors:  Małgorzata Figurska; Joanna Wierzbowska; Jacek Robaszkiewicz
Journal:  Med Sci Monit       Date:  2011-06

10.  Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model.

Authors:  E Debefve; B Pegaz; H van den Bergh; G Wagnières; N Lange; J-P Ballini
Journal:  Angiogenesis       Date:  2008-03-07       Impact factor: 9.596

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.